Milestone Achievement in Stock Price
On 16 June 2026, Integrated Proteins Ltd’s stock price surged to Rs 146.25, surpassing its previous 52-week high of Rs 145.00 by approximately 0.86%. This marks the highest valuation the stock has ever achieved, underscoring the company’s strong market presence and investor confidence. The stock opened at Rs 140.55 and maintained this level throughout the trading session, closing with a day gain of 1.99%, outperforming the Sensex’s 0.42% rise on the same day.
Performance Relative to Sector and Market Benchmarks
Despite the stock’s impressive rise, it underperformed the broader edible oil sector’s solvent extraction segment, which gained 3.83% on the day. Over the short term, Integrated Proteins Ltd has experienced a slight pullback after two consecutive days of gains, indicating a natural consolidation phase following its recent rally.
Examining the stock’s performance over various time frames reveals a compelling growth story. Over the past one month, the stock has appreciated by 17.56%, significantly outpacing the Sensex’s 1.79% gain. The three-month performance is even more striking, with a 176.78% increase compared to the Sensex’s modest 1.43% rise. Over the year, the stock has soared by 236.21%, while the Sensex declined by 6.37%. Year-to-date, Integrated Proteins Ltd has surged 325.15%, contrasting with the Sensex’s 10.13% fall. The stock’s three-year return stands at an extraordinary 1,477.67%, dwarfing the Sensex’s 20.83% gain. Over a decade, the stock has delivered a phenomenal 6,734.11% return, far exceeding the Sensex’s 188.73% growth.
Technical Indicators and Trend Analysis
The technical outlook for Integrated Proteins Ltd remains bullish. The stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, although it is slightly below the 5-day moving average, reflecting short-term price fluctuations. Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal a bullish trend on both weekly and monthly charts. The Relative Strength Index (RSI) shows a bearish signal on the weekly timeframe but no clear signal monthly, suggesting some caution in the short term.
The stock’s immediate support level is at Rs 20.71, which is also its 52-week low, while the immediate resistance was recently surpassed at Rs 136.69, the 20-day moving average area. The major resistance levels at Rs 77.10 (100-day moving average) have long been overcome, reinforcing the strength of the current uptrend. The bullish trend was established on 27 March 2026 at a price of Rs 71.33, marking a significant turning point from a previous sideways movement.
Valuation Metrics Reflect Elevated Market Expectations
Integrated Proteins Ltd’s valuation multiples indicate elevated market expectations. The price-to-earnings (P/E) ratio stands at a high 548 times trailing twelve months earnings, while the price-to-book value (P/BV) is 13.07 times. Enterprise value multiples such as EV/EBITDA and EV/EBIT both register at 268.37 times, and EV/Sales is 27.14 times. These figures suggest that investors are pricing in significant growth and profitability potential, despite the company’s current earnings base.
Dividend metrics are not applicable as the company has not declared any dividends recently, and the dividend payout ratio remains at zero. The absence of dividend yield reflects a focus on reinvestment and growth rather than income distribution.
Quality Assessment Highlights Balanced Financial Profile
The company’s overall quality grade is classified as average, based on long-term financial performance. Management risk is considered below average, while growth and capital structure are rated average and good respectively. Over the past five years, Integrated Proteins Ltd has achieved a robust sales compound annual growth rate (CAGR) of 61.22%, although EBIT growth has been more modest at 6.65%.
Financial leverage is low, with an average debt to EBITDA ratio of 0.46 and net debt to equity at zero, indicating a strong balance sheet with negligible debt. The company has no promoter share pledging, which supports shareholder confidence. However, return metrics such as average return on capital employed (ROCE) and return on equity (ROE) are weak at -4.21% and 2.06% respectively, reflecting challenges in translating sales growth into profitability.
Recent Financial Trends and Delivery Volumes
Short-term financial trends show a flat pattern as of March 2026. The company reported its highest quarterly profit after tax (PAT) of ₹0.23 crores, signalling some improvement in profitability. However, net sales over the latest six months declined by 73.53% to ₹5.69 crores, indicating a contraction in revenue during this period.
Delivery volumes have shown notable changes, with a 1-day delivery volume increase of 82.45% compared to the 5-day average, and a 1-month delivery volume growth of 36.98%. These figures suggest heightened trading activity and investor participation in recent weeks.
Summary of the Stock’s Journey to Its Peak
Integrated Proteins Ltd’s ascent to its all-time high price is the culmination of sustained sales growth, a strong balance sheet, and a bullish technical trend established earlier this year. While valuation multiples are elevated and profitability metrics remain modest, the stock’s performance relative to the broader market and sector has been exceptional. The company’s ability to maintain a micro-cap status while delivering such substantial returns over multiple time horizons highlights its unique position within the edible oil industry.
As of 16 June 2026, the stock’s market capitalisation remains classified as micro-cap, reflecting its relatively small size despite the impressive price appreciation. The recent upgrade in the Mojo Grade from Sell to Hold on 29 May 2026, with a current Mojo Score of 58.0, aligns with the stock’s improved market standing and technical momentum.
Conclusion
Integrated Proteins Ltd’s stock reaching an all-time high is a noteworthy event that encapsulates the company’s strong performance trajectory over recent years. The combination of robust sales growth, a solid capital structure, and a sustained bullish trend has propelled the stock to new heights. While valuation levels suggest cautious interpretation, the milestone reflects the company’s significant progress within the edible oil sector and its capacity to deliver substantial returns to shareholders over the long term.
